RudaCure Inc. signs recherche conjointe accord with Hanlim Pharmaceutical for traitement de la sécheresse oculaire (RCI001)
Emerging bioventure company RudaCure Inc. (PDG Yongho Kim) a signé a recherche et développement conjoints and investissement accord with Hanlim Pharmaceutical Co., Ltd. (PDG Jaeyoon Kim, Jeongjin Kim), a leading entreprise pharmaceutique in ophtalmique drugs, for the traitement de la sécheresse oculaire RCI001.
RCI001, the contrated technology, is a drug that exerts powerful anti-inflammatoire and effets antioxydants through a mechanism that suppresses activation inflammatoire, thereby alleviating sécheresse oculaire. Hanlim Pharmaceutical highly evaluated the commercialization potential of RCI001 sur la base de its faster sécrétion lacrymale, récupération des lésions cornéennes capability, and superior instillation compliance and safety compared to commercially available competing drugs, and decided to pursue joint R&D and invest in RudaCure.
The total contrat value is KRW 15 billion, comprising a fixed licence fee, separate étape clé-based royalties, and investissement funds. Hanlim Pharmaceutical will be responsible for process development, GMP production, and supply of RCI001, and will secure national sales rights and a certain equity stake in RudaCure. RudaCure will focus on R&D notamment national and international essais cliniques, ainsi que overseas licence.